Tomas J. Heyman - Jun 8, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 8, 2024
Transactions value $
$0
Form type
4
Date filed
6/11/2024, 05:25 PM
Previous filing
Jun 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +26K $0.00 26K Jun 8, 2024 Common Stock 26K $23.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in full on the earlier of (i) June 7, 2025, and (ii) the next annual meeting of the Company's stockholders, subject to the director's continued service on the Board.